Reboxetine: A Norepinephrine Selective Reuptake Pump Inhibitor

Journal of Psychiatric Practice

Volumn 10, Issue 1, 2004, Pages 57-63

  Preskorn, Sheldon H ^a,b  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE WICHITA   (United States)

^b University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ALPHA 2 ADRENERGIC RECEPTOR; AMINE; ANTIDEPRESSANT AGENT; BETA ADRENERGIC RECEPTOR; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN; CYTOCHROME P450 1A2; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; DESIPRAMINE; DOPAMINE; DULOXETINE; KETOCONAZOLE; MILNACIPRAN; MONOAMINE OXIDASE INHIBITOR; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; NORADRENALIN UPTAKE INHIBITOR; NORTRIPTYLINE; OROSOMUCOID; PLACEBO; REBOXETINE; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; YOHIMBINE;

ANORGASMIA; BRAIN NERVE CELL; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG APPROVAL; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG INDICATION; DRUG MARKETING; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG SAFETY; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG TOLERABILITY; EJACULATION DISORDER; HUMAN; INSOMNIA; LIBIDO DISORDER; MAJOR DEPRESSION; META ANALYSIS; NAUSEA; NERVE CONDUCTION; NONHUMAN; OUTCOMES RESEARCH; PHARMACOKINETICS; QT PROLONGATION; REVIEW; SIDE EFFECT; SOMNOLENCE; SWEATING; TACHYCARDIA; URINARY HESITANCY; URINE RETENTION; XEROSTOMIA;

ADRENERGIC UPTAKE INHIBITORS; ANIMALS; ANTIDEPRESSIVE AGENTS; BIOLOGICAL AVAILABILITY; CLINICAL TRIALS; CYCLOPROPANES; DEPRESSIVE DISORDER, MAJOR; DRUG APPROVAL; HUMANS; METABOLIC CLEARANCE RATE; MORPHOLINES; THIAZEPINES; THIOPHENES; UNITED STATES;

EID: 1642499237     PISSN: 15274160     EISSN: None     Source Type: Journal    
DOI: 10.1097/00131746-200401000-00006     Document Type: Review

References (45)

1. Preskorn SH. Understanding the basics of antidepressant pharmacology. Series of columns published in the Journal of Psychiatric Practice between 1998 and 2000 (www.preskorn. com/column2.html).
2. Preskorn SH. Modern drug development and the Human Genome Project. Series of columns published in the Journal of Psychiatric Practice between 2000 and 2002 (www.preskorn. com/column4.html).
3. Preskorn SH. The polypharmacology section. Series of columns published in the Journal of Psychiatric Practice between 1997 and 2003 (www.preskorn.com/columnl.html).
4. Frigerio E, Benecchi A, Brianceschi G, et al. Pharmakonetics of reboxetine enantiomers in the dog. Chirality 1997;9:303-6.
5. Fleishaker JC. Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression. Clin Pharmacokinet 2000;39:413-27.
6. Raggi MA, Mandrioli R, Sabbioni C, et al. Chronic treatment with reboxetine by means of capillary electrophoresis. Electrophoresis 2002;23:1870-7.
7. Invernizzi RW, Parini S, Sacchetti G, et al. Chronic treatment with reboxetine by osmotic pumps facilitates its effect on the extracellular noradrenaline and may desensitize alpha (2)-adrenoceptors in the prefrontal cortex. Br J Pharmacol 2001; 132:183-8.
8. Szabo ST, Blier P. Effects of the selective noradrenergic reuptake inhibitor reboxetine on the firing activity of noradrenaline and serotonin neurons. Eur J Neurosci 2001;13:2077-87.
9. Szabo ST, Blier P. Effects of the selective norepinephrine reuptake inhibitor reboxetine on norepinephrine and serotonin transmission in the rat hippocampus. Neuropsychopharmacology 2001;25:845-57.
10. Linner L, Endersz II, Ohman D, et al. Reboxetine modulates the firing pattern of dopamine cells in the ventral tegmental area and selectively increases dopamine availability in the prefrontal cortex. J Pharmacol Exp Ther 2001;297:540-6.
11. Cryan JF, Dalvi A, Jin SH, et al. Use of dopamine-betahydroxylase-deficient mice to determine the role of norepinephrine in the mechanism of action of antidepressant drugs. J Pharmacol Exp Ther 2001;298:651-7.
12. Manier DH, Shelton RC, Sulser F. Noradrenergic antidepressants: Does chronic treatment increase or decrease nuclear CREB-P? J Neural Transm 2002;109:91-9.
13. Miller DK, Wong EH, Chesnut MD, et al. Reboxetine: Functional inhibition of monoamine transporters and nicotinic acetylcholine receptors. J Pharmacol Exp Ther 2002;302: 687-95.
14. Anonymous. Enhancement of human cortico-motoneuronal excitability by the selective norepinephrine reuptake inhibitor reboxetine. Neurosci Lett 2002;330:231-4.
15. Papps BP, Shajahan PM, Ebmeier KP, et al. The effects of noradrenergic re-uptake inhibition on memory encoding in man. Psychopharmacology 2002;159:311-8.
16. Tse WS, Bond AJ. Difference in serotonergic and noradrenergic regulation of human social behaviors. Psychopharmacology 2002;159:216-21.
17. Wienkers LC, Allievi C, Hauer MJ, et al. Cytochrome P-450-mediated metabolism of the individual enantiomers of the antidepressant agent reboxetine in human liver microsomes. Drug Metab Dispos 1999;27:1334-40.
18. Edwards DM, Pellizzoni C, Breuel HP, et al. Pharmacokinetics of reboxetine in healthy volunteers: Single oral doses, linearity and plasma protein binding. Biopharm Drug Dispos 1995;16:443-60.
19. Pellizzoni C, Poggesi I, Jorgensen NP, et al. Pharmacokinetics of reboxetine in healthy volunteers: Single against repeated oral doses and lack of enzymatic alterations. Biopharm Drug Dispos 1996;17:623-33.
20. Dostert P, Benedetti MS, Poggesi I. Review of the pharmacokinetics and metabolism of reboxetine, a selective noradrenaline reuptake inhibitor. Eur Neuropsychopharmacol 1997;7(suppl 1):S23-S35.
21. Rey E, Dostert P, D'Athis P, et al. Dose proportionality of reboxetine enantiomers in healthy male volunteers. Biopharm Drug Dispos 1999;20:177-81.
22. Hendershot PE, Fleishaker JC, Lin KM, et al. Pharmacokinetics of reboxetine in healthy volunteers with different ethnic descents. Psychopharmacology (Berl) 2001;155:148-53.
23. Bergmann JF, Laneury JP, Duchene P, et al. Pharmacokinetics of reboxetine in healthy, elderly volunteers. Eur J Drug Metab Pharmacokinet 2000;25:195-8.
24. Poggesi I, Pellizzoni C, Fleishaker JC. Pharmacokinetics of reboxetine in elderly patients with depressive disorders. Int J Clin Pharmacol Ther 2000;38:254-9.
25. Coulomb F, Ducret F, Laneury JP, et al. Pharmacokinetics of single-dose reboxetine in volunteers with renal insufficiency. J Clin Pharmacol 2000;40:482-7.
26. Herman BD, Fleishaker JC, Brown MT. Ketoconazole inhibits the clearance of the enantiomers of the antidepressant reboxetine in humans. Clin Pharmacol Ther 1999;66:374-9.
27. Spina E, Avenoso A, Scordo MG, et al. No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites. Ther Drug Monit 2001;23:675-8.
28. Scates AC, Doraiswamy PM. Reboxetine: A selective norepinephrine reuptake inhibitor for the treatment of depression. Ann Pharmacother 2000;34:1302-12.
29. Tanum L. Reboxetine: Tolerability and safety profile in patients with major depression. Acta Psychiatr Scand Suppl 2000;402:37-40.
30. Andreoli V, Carbognin G, Abati A, et al. Reboxetine in the treatment of depression in the elderly: Pilot study. J Geriatr Psychiatry Neurol 1999;12:206-10.
31. O'Flynn R, Michael A. Reboxetine-induced spontaneous ejaculation. Br J Psychiatry 2000;177:567-8.
32. Benazzi F. Urinary retention with reboxetine-fluoxetine combination in a young man. Can J Psychiatry 2000;45:936.
33. Demyttenaere K, Huygens R. Painful ejaculation and urinary hesitancy in association with antidepressant therapy: Relief with tamsulosin. Eur Neuropsychopharmacol 2002;12:337-41.
34. Kasper S. Managing reboxetine-associated urinary hesitancy in a patient with major depressive disorder: A case study. Psychopharmacology (Berl) 2002;159:445-6.
35. Fleishaker JC, Francom SF, Herman BD, et al. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001;70:261-9.
36. Agelink MW, Ullrich H, Passenberg P, et al. Superior safety of reboxetine over amitryptiline in the elderly. Eur J Med Res 2002;7:415-6.
37. Ferguson JM, Mendels J, Schwart GE. Effects of reboxetine on Hamilton Depression Rating Scale factors from randomized, placebo-controlled trials in major depression. Int Clin Psychopharmacol 2002;17:45-51.
38. Andreoli V, Caillard V, Deo RS, et al. Reboxetine, a new noradrenaline selective antidepressant, is at least as effective as fluoxetine in the treatment of depression. J Clin Psychopharmacol 2002;22:393-9.
39. Versiani M, Mehilane L, Gaszner P, et al. Reboxetine, a unique selective NRI, prevents relapse and recurrence in long-term treatment of major depressive disorder. J Clin Psychiatry 1999;60:400-6.
40. Versiani M, Amin M, Chouinard G. Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. J Clin Psychopharmacol 2000;20:28-34.
41. Massana J, Moller HJ, Burrows GD, et al. Reboxetine: A double-blind comparison with fluoxetine in major depressive disorder. Int Clin Psychopharmacol 1999;14:73-80.
42. Venditti LN, Arcelus A, Birnbaum H, et al. The impact of antidepressant use on social functioning: Reboxetine versus fluoxetine. Int Clin Psychopharmacol 2000;15:279-89.
43. Healy D. Reboxetine: Its effects as measured by the Social Adaptation Self-Evaluation Scale. Acta Psychiatr Scand Suppl 2000;402:45-51.
44. Keller M. Role of serotonin and noradrenaline in social dysfunction: A review of data on reboxetine and the Social Adaptation Self-evaluation Scale (SASS). Gen Hosp Psychiatry 2001;23:15-9.
45. Massana J. Reboxetine versus fluoxetine: An overview of efficacy and tolerability. J Clin Psychiatry 1998;59(S14):8-10.